Han Kun Law Offices

Legal Services | Mainland China, China
tel: (86 755) 3680 6500 | fax: (86 755) 3680 6599
20/F, Kerry Plaza Tower 3, 1-1 Zhongxinsi Road, Futian District | Shenzhen | Mainland China | 518048 | China

Main Contacts

Overview

Han Kun is a leading full-service law firm in China. Over the years, Han Kun has been widely recognized as a leader in complex cross-border and domestic transactions and compliance matters.

Our main practice areas include private equity, mergers and acquisitions, international and domestic capital markets, investment funds, asset management, compliance, banking and finance, aviation finance, foreign direct investment, antitrust/competition, data protection, private client/wealth management, intellectual property, bankruptcy and restructuring and dispute resolution.

We have more than 1000 professionals located in Beijing, Shanghai, Shenzhen, Hangzhou, Wuhan, Haikou, Hong Kong, Singapore, New York, Silicon Valley and London.

All our lawyers are graduates of top universities and have extensive experience in complex cross-border transactions and dispute resolution as counsel to both Chinese and foreign clients.

Our working languages include Chinese, English, Japanese, Korean and German.

Year this Office was Founded: 1994
Lawyers Worldwide: 900

Areas of Practice

Professionals

Partners

Articles

The Regulatory Data Protection System Takes Effect, Injecting New Vitality into Innovative Drug Transactions – An Analysis of the Implementation Measures for Regulatory Data Protection

On March 19, 2025, the General Affairs Department of the National Medical Products Administration ("NMPA") issued theImplementation Measures for Regulatory Data Protection (Trial, Draft for Comments)(the "Draft for Comments") and theWorking Procedures for Regulatory Data Protection (Draft for Comments)to further advance the implementation of the Regulatory Data Protection system (the "RDP System")(For an analysis of these two documents, please refer to our previously published article:A New Perspective on Innovative Drug Transactions: Analysis of the New Draft of the Regulatory Data Protection System (Bilingual))...

Spring Breeze on the Shore: New rules on RMB Cross-Border Interbank Financing and Banks' Suggested Responses

On February 26, 2026, the People's Bank of China ("PBoC") promulgated theNotice on Relevant Matters Concerning Cross-border RMB Interbank Financing Business of Banking Financial Institutions(Yin Fa [2026] No. 51, the "Notice"). Previously, on September 12, 2025, the PBoC issued theNotice of the PBoC on Relevant Matters Concerning Cross-border RMB Interbank Financing Business of Banking Financial Institutions (Draft for Comments)(the "Draft")...

VIEW ALL Han Kun Law Offices Articles

Press releases

Han Kun Hong Kong advised Joint Lead Managers on Fujian Zhanglong Group Co., Ltd's CNY3,056 million Bond Issuance

Han Kun Law Offices LLP ("Han Kun Hong Kong"), acting as the international legal counsel to the Joint Lead Managers and the Trustee, advised Fujian Zhanglong Group Co., Ltd. ("Fujian Zhanglong Group") on the successful issuance of the RMB3,056 million five-year offshore sustainable bonds (the "Bonds"). The coupon rate of the 5-year Bonds is 2.35%.This issuance set a new record low for offshore Renminbi bond coupon rates among Fujian provincial state-owned enterprises, attracting broad attention and strong support from international investors, achieving 6x oversubscription, with the final coupon rate significantly tightened by 75 basis points from the initial price guidance...

Han Kun Advises CrystalO on the Collaboration and License Agreement with Almirall for the Discovery and Development of Novel Small Molecules in Medical Dermatology

On 10 August 2026, Shenzhen CrystalO Biopharma Co., Ltd. ("CrystalO") announced that it has entered into a Collaboration and License Agreement with Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, Spain ("Almirall").Under the terms of the agreement, CrystalO will leverage its leading AI- and structure-based drug discovery platform to conduct candidate compound discovery, optimization, IND-enabling studies and early clinical development, to advance the program through proof of concept (POC) clinical testing...

VIEW ALL Han Kun Law Offices Press
dots